Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel-PM in Recurrent or Metastatic HNSCC
NCT02639858Phase 2Unknown
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Oct 2015
- Primary completion
- Sep 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Nanoxel M in head and neck squamous cell carcinoma (HNSCC), sponsored by Samyang Biopharmaceuticals Corporation. Status: unknown.
02
Drugs
Nanoxel M
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02639858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639858.